Navigation Links
Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
Date:12/6/2007

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Epiphany Biosciences announced today, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. Currently, there are no approved therapeutics for the treatment for this debilitating condition or any other disease caused by the Epstein-Barr virus (EBV)

"Valomaciclovir has shown a broad spectrum of anti-viral activity, including inhibition of viral replication of herpes zoster and EBV," said Fred Volinsky, MD, Chief Executive Officer. "EBV has been implicated in a number of chronic and transplant-related diseases. This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent. We are pleased to be working with the University of Minnesota on this important project".

"EBV is a highly prevalent virus, with up to 95% of middle-aged adults possessing evidence of viral exposure according to CDC surveillance data," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can severely undermine quality-of-life and the acute EBV infection may lead to other long-term medical sequelae. This double-blind, placebo-controlled, clinical trial will examine fluctuations in viral load as influenced by valomaciclovir as well as assess symptom scores."

"Our laboratory has found valomaciclovir to be a very potent anti-viral agent against EBV", reported Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this proof of concept study is successful, further large scale studies are warranted. We urgently need a solution for this disease that can severely impact the lives of young adults."

The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against EBV related diseases. Comparative anti-EBV potency data were presented by Professor Balfour's team at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago in September. A manuscript containing additional data confirming the unique susceptibility of EBV to valomaciclovir will be submitted to a peer-reviewed scientific journal shortly.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany is currently conducting a large Phase 2b study examining the safety and efficacy of valomaciclovir against herpes zoster infection.

Epiphany was founded by a world-class virology team, including two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website http://www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193


'/>"/>
SOURCE Epiphany Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 Amarantus ... focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... will be presenting at two upcoming investor conferences: ... 730 Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... a half of planning the Multiple Pathways of Recovery Conference , CCAR is pleased ... held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... pathways individuals use to get into and sustain their recovery. Pathways of recovery are ...
(Date:5/27/2016)... ... 2016 , ... Southland Log Homes , designer and manufacturer of America’s ... which can be found on its website at SouthlandLogHomes.com. , The designs of the ... highlight the craftsmanship of timber post and beam construction. The result is a ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign ... inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also provides ... associations and industry leaders such as Bioness. , As patients feel increasingly ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
Breaking Medicine News(10 mins):